CRISPR Therapeutics
CRSP
CRSP
155 hedge funds and large institutions have $631M invested in CRISPR Therapeutics in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 52 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
155
Holders Change
-24
Holders Change %
-13.41%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
30
Increased
41
Reduced
44
Closed
52
Calls
$11.4M
Puts
$17.5M
Net Calls
-$6.11M
Net Calls Change
+$20.4M
Top Buyers
Top Sellers
| 1 |
1
Jennison Associates
New York
|
$0 |
| 2 |
O
2
OrbiMed
New York
|
$0 |
| 3 |
CC
3
Casdin Capital
New York
|
$0 |
| 4 |
EC
4
EcoR1 Capital
San Francisco,
California
|
$5.97M |
| 5 |
5
JPMorgan Chase & Co
New York
|
$1.48M |
